OMIC Stock Overview
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Singular Genomics Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.68 |
| 52 Week High | US$10.29 |
| 52 Week Low | US$1.80 |
| Beta | 0 |
| 1 Month Change | 33.08% |
| 3 Month Change | 11.92% |
| 1 Year Change | -66.14% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| OMIC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.7% | -0.03% | 1.7% |
| 1Y | -66.1% | -15.2% | -12.5% |
Return vs Industry: OMIC underperformed the US Life Sciences industry which returned -14.5% over the past year.
Return vs Market: OMIC underperformed the US Market which returned -13.6% over the past year.
Price Volatility
| OMIC volatility | |
|---|---|
| OMIC Average Weekly Movement | 13.7% |
| Life Sciences Industry Average Movement | 11.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: OMIC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: OMIC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 269 | Drew Spaventa | https://singulargenomics.com |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution.
Singular Genomics Systems, Inc. Fundamentals Summary
| OMIC fundamental statistics | |
|---|---|
| Market Cap | US$190.98m |
| Earnings (TTM) | -US$89.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs OMIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMIC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$89.54m |
| Earnings | -US$89.54m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.6% |
How did OMIC perform over the long term?
See historical performance and comparison